Arena weight-loss trial disappoints investors (Reuters)
Reuters - Arena Pharmaceuticals Inc's obesity drug disappointed investors in a second big clinical trial, sending shares plunging 33 percent on Friday from their highs on Thursday night.
Blog Content
Posts
